BZD9L1 benzimidazole analogue hampers colorectal tumor progression by impeding angiogenesis

Figure 6 Tumor growth analyses of HCT116 tumor xenograft in nude mice. Treatments were administered when the tumors reached 100 mm³. A: Relative tumor volume; B: Tumor weight and; C: Percentage body weight change in mice treated with vehicle control (0.5% carboxymethylcellulose), BZD9L1 (50 mg/kg per 3 d, BZD9L1 (250 mg/kg per 3 d) and sunitinib (40 mg/kg per 3 d) as the positive control; D: Tumor necrosis percentage in sections stained with haematoxylin and eosin. N indicates necrotic tissues; E: Ki67 proliferation protein expression in treated and vehicle control groups. Statistical analysis (^aP < 0.05; ^bP < 0.01; ^cP < 0.001). The non-linear fit was used to track the tumor size and body weight change over time, one-way ANOVA with Bonferroni posthoc test for tumor weight, n = 6 animals per group) using GraphPad Prism 9.4.0. Error bars represent SEM. VC: Vehicle control.